Identification of Cys255 in HIF‐1α as a novel site for development of covalent inhibitors of HIF‐1α/ARNT PasB domain protein–protein interaction
暂无分享,去创建一个
Ping Chen | Simon Bergqvist | Kevin K-C Liu | H Jane Dyson | Jiangli Yan | Carol L Nilsson | H. Dyson | Ping Chen | Jiangli Yan | C. Nilsson | K. Liu | A. Brooun | S. Bergqvist | Ya-li Deng | M. Greig | D. Nowlin | Ya-Li Deng | Rosa Cardoso | R. Love | Jing Zhu | Alexei Brooun | Michael J Greig | Rosa Cardoso | Robert Love | Dawn Nowlin | Jing Zhu | Kevin K.‐C. Liu
[1] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[2] D. Fattori,et al. Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.
[3] K. Gardner,et al. Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet interface for hetero- and homodimerization. , 2005, Journal of molecular biology.
[4] H. Jhoti,et al. Fragment-based drug discovery using rational design. , 2007, Ernst Schering Foundation symposium proceedings.
[5] P. Ratcliffe,et al. Regulation of HIF: prolyl hydroxylases. , 2006, Novartis Foundation symposium.
[6] G. Semenza. HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.
[7] Scott B Ficarro,et al. A structure-guided approach to creating covalent FGFR inhibitors. , 2010, Chemistry & biology.
[8] James B. Mitchell,et al. PX‐478, an inhibitor of hypoxia‐inducible factor‐1α, enhances radiosensitivity of prostate carcinoma cells , 2008, International journal of cancer.
[9] R. Hammer,et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.
[10] M. Westergaard,et al. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth , 2008, Molecular Cancer Therapeutics.
[11] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[12] David Baker,et al. Quantitative reactivity profiling predicts functional cysteines in proteomes , 2010, Nature.
[13] A. Harris,et al. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions , 2012, Expert opinion on therapeutic targets.
[14] J. Wells,et al. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.
[15] J F Brandts,et al. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. , 1989, Analytical biochemistry.
[16] H. Dyson,et al. Homodimerization of the PAS-B domains of hypoxia-inducible factors. , 2012, The journal of physical chemistry. B.
[17] S. McKnight,et al. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.
[18] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[19] J. H. Ward. Hierarchical Grouping to Optimize an Objective Function , 1963 .
[20] D. Kufe,et al. Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179* , 2006, Journal of Biological Chemistry.
[21] Zhaobin Zhang,et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. , 2005, Cancer research.
[22] Michael S. Cohen,et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.
[23] Erwin G. Van Meir,et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. , 2011, Journal of medicinal chemistry.
[24] Daniel A Erlanson,et al. Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.
[25] Kevin H. Gardner,et al. Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor , 2009, Proceedings of the National Academy of Sciences.
[26] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[27] Clemens Vonrhein,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[28] Olof Ramström,et al. Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.
[29] D. Kufe,et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. , 2006, The Journal of biological chemistry.
[30] M. Yoshimura,et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels , 2012, Nature Communications.
[31] V. Haase. The VHL tumor suppressor: master regulator of HIF. , 2009, Current pharmaceutical design.
[32] K. Gardner,et al. Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[34] Å. Borg,et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.
[35] Lei Zhang,et al. Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor* , 2005, Journal of Biological Chemistry.
[36] Valerie Daggett,et al. Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B. , 2009, Journal of the American Chemical Society.
[37] G. Semenza. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.
[38] M. Konopleva,et al. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] W. Denny,et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] B. Cravatt,et al. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.
[41] M. Konopleva,et al. A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells , 2006, Clinical Cancer Research.
[42] N. Foloppe. The benefits of constructing leads from fragment hits. , 2011, Future medicinal chemistry.
[43] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[44] Yate-Ching Yuan,et al. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. , 2011, ACS chemical biology.
[45] Y. Soh,et al. Rapid degradation of hypoxia‐inducible factor‐1α by KRH102053, a new activator of prolyl hydroxylase 2 , 2008, British journal of pharmacology.